Výsledky vyhledávání

Akademický článek

Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block in vitro granzyme-mediated target cell killing by CD8 T or NK cells.

Autor: Sutton VR; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Watt SV; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Akhlaghi H; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Cipolla DC; Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Insmed Incorporated, Bridgewater, NJ, United States., Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Munoz I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Hodel AW; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Noori T; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Voskoboinik I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2024 Jul 03; Vol. 15, pp. 1396710. Date of Electronic Publication: 2024 Jul 03 (Print Publication: 2024).

Zobrazit plný text záznamu

Akademický článek

Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.

Autor: McDonald PP; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Leifer FG; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Basso J; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Lasala D; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Li D; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Zhang J; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Perkins WR; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Cipolla DC; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Aug 11; Vol. 14, pp. 1231047. Date of Electronic Publication: 2023 Aug 11 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.

Autor: Basso J; Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Insmed Incorporated, Bridgewater, NJ, United States., Zhou Y; Insmed Incorporated, Bridgewater, NJ, United States., Mark L; Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Insmed Incorporated, Bridgewater, NJ, United States., Dorfman A; Insmed Incorporated, Bridgewater, NJ, United States., Atalla M; Insmed Incorporated, Bridgewater, NJ, United States., Chun D; Insmed Incorporated, Bridgewater, NJ, United States., Viramontes V; Insmed Incorporated, Bridgewater, NJ, United States., Chang C; Insmed Incorporated, Bridgewater, NJ, United States., Leifer F; Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Insmed Incorporated, Bridgewater, NJ, United States., Cipolla DC; Insmed Incorporated, Bridgewater, NJ, United States.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2023 Jul 19; Vol. 14, pp. 1208780. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.

Autor: Chen KJ; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Zhang J; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Basso J; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Chun D; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Zhou Y; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Perkins WR; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Cipolla DC; Research Department of Insmed Incorporated, Bridgewater, NJ, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jun 27; Vol. 14, pp. 1185727. Date of Electronic Publication: 2023 Jun 27 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery.

Autor: Plaunt AJ; Insmed Incorporated, Bridgewater, NJ 08807, USA., Nguyen TL; Insmed Incorporated, Bridgewater, NJ 08807, USA., Corboz MR; Insmed Incorporated, Bridgewater, NJ 08807, USA., Malinin VS; Insmed Incorporated, Bridgewater, NJ 08807, USA., Cipolla DC; Insmed Incorporated, Bridgewater, NJ 08807, USA.

Publikováno v: Pharmaceutics [Pharmaceutics] 2022 Jan 27; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 27.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání